Fig. 4.

Change in body weight from baseline with oral semaglutide versus comparators in PIONEER trials. All data are for the treatment policy estimand at the end of treatment. Body weight changes have not previously been published for PIONEER 9 or PIONEER 10 and so are excluded. *Statistically significant estimated treatment difference (p < 0.05) in favor of oral semaglutide versus competitor or placebo; ^#Statistically significant difference (p < 0.05) in favor of oral semaglutide versus competitor and placebo. Empa, empagliflozin; lira, liraglutide; pbo, placebo; PIONEER, peptide innovation for early diabetes treatment; sema, semaglutide; sita, sitagliptin